Lyndsey Runaas, MD

Assistant Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Lyndsey Runaas, MD, is an Instructor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in leukemia and allogeneic stem cell transplant at Froedtert Hospital. She graduated with Alpha Omega Alpha Honor Society membership from the University of Wisconsin School of Medicine and Public Health in 2010. She then completed her Internal Medicine residency at the University of Wisconsin in Madison, Wisconsin in 2013, and served as Chief Resident in 2014. Following this, she completed her fellowship in Hematology and Oncology at the University of Michigan in 2017. Her clinical focus is on myeloid malignancies and allogeneic stem cell transplant with research interests in patient-physician communication and patient reported outcomes. Her professional memberships include the American Society of Hematology, American Society of Clinical Oncology and American Society for Blood and Marrow Transplantation.

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.

(Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E.) Haematologica. 2024 Apr 04 PMID: 38572562 04/04/2024
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.

(Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M.) Bone Marrow Transplant. 2024 Mar;59(3):373-379 PMID: 38177221 SCOPUS ID: 2-s2.0-85181508004 01/05/2024
Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy.

(Taylor S, Murthy GSG, Runaas L, Michaelis LC, Carlson K, Atallah EL, Abedin SM.) Leuk Res. 2023 Sep;132:107348 PMID: 37423073 SCOPUS ID: 2-s2.0-85164434355 07/10/2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

(Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators.) N Engl J Med. 2023 Jun 22;388(25):2338-2348 PMID: 37342922 PMCID: PMC10575613 06/21/2023
Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination.

(Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR.) Haematologica. 2023 Jan 01;108(1):250-256 PMID: 36106394 PMCID: PMC9827178 SCOPUS ID: 2-s2.0-85145424654 09/16/2022
Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia.

(Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, Atallah E.) Leuk Res. 2022 Dec;123:106984 PMID: 36401944 SCOPUS ID: 2-s2.0-85141943453 11/20/2022
Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885].

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Transplant Cell Ther. 2022 Oct;28(10):717 PMID: 36202527 SCOPUS ID: 2-s2.0-85101258094 10/07/2022
Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.

(Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS.) Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e495-e497 PMID: 35148976 PMCID: PMC8767926 SCOPUS ID: 2-s2.0-85132179962 02/13/2022
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients.

(Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M.) Cancer Cell. 2022 Apr 11;40(4):340-342 PMID: 35202585 PMCID: PMC8864440 SCOPUS ID: 2-s2.0-85127542763 02/25/2022
Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885, (S1083879120304146), (10.1016/j.bbmt.2020.07.005)]

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Transplantation and Cellular Therapy. October 2022;28(10):717 SCOPUS ID: 2-s2.0-85101258094 10/01/2022
Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome.

(Corrao K, Rezwan S, Atallah E, Michaelis LC, Runaas L, Harrington AM, Abedin S.) Leuk Res Rep. 2022;17:100329 PMID: 35651540 PMCID: PMC9150024 SCOPUS ID: 2-s2.0-85131561638 06/03/2022
Acute Myelogenous Leukemia

(Jones MA, Runaas L, Khoriaty RN, Bixby D.) Oncology Board Review: Blueprint Study Guide and Q&A: Third Edition. 1 January 2021:3-21 SCOPUS ID: 2-s2.0-85169382701 01/01/2021